## Supplementary material

## Serum IL-7 as diagnostic biomarker for rheumatoid arthritis, validation with EULAR-2010 classification criteria

Using the ACR 1987 criteria, out of $\mathrm{n}=197$ with available clinical information, 62 patients were diagnosed with RA and 137 with non-RA conditions. Follow up diagnosis was missing in $\mathrm{n}=58$ cases. The 58 missing patients were due to change in clinical practice and the absence of records for ACR1987 criteria. Clinical and laboratory characteristics are shown in Table S1.
We confirmed significant differences between RA and non-RA for ACPA, RF, SE, TJC, SJT, CRP, DAS28. In the regression model (Table S2), data were also reproduced suggesting a role for IL-7 as biomarker for RA, notably in ACPA-negative patients.

Table S1. Descriptive characteristics of patients based on the ACR 1987' criteria ( $\mathrm{n}=197$ ). *4 patients with EULAR 2010 RA never satisfied the ACR 1987 criteria and changed groups.

| Variable | non-RA <br> $\mathrm{n}=137^{*}$ | RA <br> $\mathrm{n}=62$ | $p$-value* |
| :--- | :---: | :---: | :---: |
| Age (years) | $50.0(41.0-63.0)$ | $62.0(51.0-70.8)$ | $<0.0001$ |
| ACPA (pos/neg) | $7 / 125$ | $43 / 19$ | $<0.0001$ |
| RF (pos/neg) | $14 / 117$ | $39 / 23$ | $<0.0001$ |
| SE (pos/neg) | $54 / 77$ | $45 / 17$ | $<0.0001$ |
| DAS28 CRP | $3.2(2.3-3.95)$ | $4.1(3-4.8)$ | $<0.0001$ |
| Smoking (current/never/previous) | $21 / 45 / 39$ | $13 / 23 / 26$ | 0.001 |
| SJC | $1(0-3)$ | $3(0-8)$ | 0.002 |
| TJC | $3(1-7)$ | $6(2-12)$ | 0.023 |
| CRP (mg/L) | $5.3(5.0-18.4)$ | $11.6(5.0-24.0)$ | 0.072 |
| IL-7 pg/ul | $17.9(13.5-26.9)$ | $16.65(13.6-21.4)$ | 0.056 |
| BMI | $27.6(17-49)$ | $26.7(16-47)$ | 0.116 |
| HAQ** | $6(2-10)$ | $7(3-11)$ | 0.353 |
| Disease duration (months) | $4(3-6)$ | $4(3-6)$ | 0.604 |
| Gender (F/M) | $91 / 46$ | $43 / 19$ | 0.958 |

Data are median and interquartile range (IQR).
**Data missing in 53 cases.

Table S2. Regression models for RA patients diagnosed according to the ACR 1987 criteria.

| Covariate | Unadjusted OR | Adjusted OR | Adjusted $p$-value |
| :--- | :---: | :---: | :---: |
| Model 1 |  |  |  |
| ACPA | $40.41(15.89,102.77)$ | $43.84(14.67,131.01)$ | $<0.001$ |
| CRP | $1.01(1.00,1.03)$ | $1.03(1.01,1.05)$ | 0.009 |
| IL7 | $0.96(0.92,1.00)$ | $0.94(0.88,1.00)$ | 0.042 |
| TJC | $1.05(1.00,1.09)$ | $1.08(1.00,1.17)$ | 0.061 |
| SJC | $1.12(1.04,1.19)$ | $1.00(0.89,1.13)$ | 0.988 |
| Pseudo $R^{2}=0.584$, AUROC $=0.889$ |  |  |  |
| Model 2 |  |  |  |
| CRP | $1.02(1.00,1.03)$ | $1.03(1.01,1.05)$ | 0.014 |
| TJC | $1.05(0.99,1.12)$ | $1.09(1.00,1.18)$ | 0.049 |
| IL7 | $0.98(0.92,1.05)$ | $0.93(0.86,1.01)$ | 0.100 |
| SJC | $1.04(0.93,1.16)$ | $0.95(0.82,1.09)$ | 0.453 |
| Pseudo $R^{2}=0.136$, AUROC $=0.705$ |  |  |  |

Model S1 uses all patients ( $\mathrm{n}=169$ ); variables included ACPA, IL7, SJC, TJC, CRP.
Model S2 uses only ACPA negative patients ( $\mathrm{n}=121$ ), variables included IL7, SJC, TJC, CRP.

